ALMKT:EPA
Mauna Kea Technologies SA
0,095 €
arrow_upward
+1,39%(+0,0013) 1 d.
11. nov., 17:35:24 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALMKT…
Atvērt
0,09 €
Augsta
0,10 €
Zema
0,09 €
Tirgus kapitalizācija
19,15 milj.
Vid. apjoms
552,82 tūkst.
Apjoms
401,36 tūkst.
Cenas/peļņas attiecība
0,81
Augstākā 52 ned.
0,23 €
Zemākā 52 ned.
0,07 €
Peļņa uz vienu akciju
0,12 €
Apgrozībā esošās akcijas
195,26 milj.
Darbinieku skaits
56
Atvērt
0,09 €
Augsta
0,10 €
Zema
0,09 €
Tirgus kapitalizācija
19,15 milj.
Vid. apjoms
552,82 tūkst.
Apjoms
401,36 tūkst.
Cenas/peļņas attiecība
0,81
Augstākā 52 ned.
0,23 €
Zemākā 52 ned.
0,07 €
Peļņa uz vienu akciju
0,12 €
Apgrozībā esošās akcijas
195,26 milj.
Darbinieku skaits
56
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
MarketWatch
·
pirms 19 minūtēm
Nasdaq futures fall as Nvidia sinks 8% after hours on report board may oust Huang
The Globe and Mail
·
pirms 1 stundas
Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years
TradingView
·
pirms 1 stundas
Nasdaq 100 Futures Drop As Reports Relating To Jensen Huang’s Ousting Outweigh CoreWeave’s Strong Outlook — NVDA, TSLA, SNDK, CAPR, CRWV In Focus
Bloomberg
·
pirms 3 stundām
Nasdaq 100 Advances 3% as Easing AI Anxiety Draws Dip Buyers In
Profils
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Par “Mauna Kea Technologies SA”
ĢenerāldirektorsSacha Loiseau
Darbinieki56
Dibināšanas datums2000
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnemaunakeatech.com